Effects of Serial Plotting on Fundal Height Charts on Identification and Outcomes of Small for Gestational Age Infants
Effects of Serial Plotting on Fundal Height Charts on Identification and Outcomes of Small for Gestational Age Infants
Fetal Growth Restriction (FGR) remains a challenging topic for clinicians, researchers and policy makers, and a central question is how to improve the performance of screening during pregnancy in order to provide appropriate care. The recent recommendations and reporting of French results have raised awareness of the need to improve growth screening in France. Based on the existing literature, the hypothesis is that a greater investment in growth monitoring based on a more rigorous interpretation of information available from routinely implemented clinical assessment and ultrasound will allow for significant gains in detection. The current context provides the opportunity to evaluate the application of a training program for serial plotting of Symphysis Fundal Height (SFH) and Estimated Fetal Weight (EFW) on customised charts. This intervention is consistent with French guidelines which support the monthly measurement of SFH, the use of Customised Fetal Weight Reference (CFWR), in particular for referral US (Ultrasound) examinations, and the longitudinal interpretation of growth. These guidelines were recently restated in the clinical practice recommendations issued by the French College of Obstetricians and Gynecologists.
The intervention tested in the trial will include training of professionals for standardization of SFH measurement, introduction of software, and recommendations for growth interpretation and referral examinations. Expected benefits are an increase in antenatal identification of growth restricted fetuses without an increase in the FP rate. Such a program will allow identified Small for Gestational Age (SGA) fetuses to receive appropriate antenatal care. This intervention could double the detection rate of SGA births from 20 to 40%, corresponding to 32 000 infants nationwide annually for whom antenatal care could be improved.
Main objective: To test the effectiveness of the serial plotting of SFH and EFW measures on customised percentile charts supported by provider training, versus standard antenatal care, to improve the detection of FGR. The aim of the investigators is to double rates of antenatal detection from 20 to 40% among SGA infants, defined as a birthweight under the 10th percentile for GA.
Type of study Randomized cluster trial
Study objectives:
Main objective : To test the effectiveness of the serial plotting of SFH and EFW measures on customised percentile charts supported by provider training, versus standard antenatal care, to improve the detection of FGR. Our aim is to double rates of antenatal detection from 20 to 40% among SGA infants, defined as a birthweight under the 10th percentile for GA.
Secondary objectives: To measure the impact of screening program on:
Primary endpoint
Detection of FGR during pregnancy, defined as:
Secondary endpoints
Inclusion criteria : Singleton pregnancy, Booking before or at 30 weeks GA in the maternity units , Delivery in the participating units Exclusion criteria : Terminations of pregnancy, Known fibroid uterus or uterine congenital malformations, Refusal to participate, Minor patient
HPAG is a cluster randomized trial involving 16 geographically dispersed French maternity units. In the maternity units randomized to the intervention group, a protocol of growth monitoring supported by prior training of healthcare professionals will be implemented for all pregnant women receiving antenatal care in the unit, whatever the GA or medical or obstetrical risk.
The intervention consists only in the standardization of current practices. Clinicians in the intervention maternity units will follow a standardized protocol, and will be asked to measure SFH at each antenatal appointment, collect EFW from the 3rd trimester US, report these values on the chart, and monitor fetal growth according to the protocol guidelines. Practices will remain unchanged in the control group.
After delivery, inclusion and exclusion criteria will be assessed by independent clinical research investigators, probably midwives. All SGA births and non-SGA births according to the French CFWR will be included to answer the main and secondary objectives.
Data collection will be carried out by the referent midwife. Recorded information will include the antenatal care provided, suspicion of FGR, labor and delivery modes, and neonatal outcomes until discharge home. The use of the intervention will also be assessed in the intervention maternity units by recording information on the presence and completeness of customised charts in the medical records.
Sites : 16 French maternity units
Duration : 24 months, including 6 months of inclusions
Number of participants : 10 000 births (625 per maternity unit)
Inclusion Criteria:
Mothers will be recruited after delivery if they fulfill the following criteria:
Exclusion Criteria:
Eric.Verspyck@chu-rouen.fr
apicolet@chu-grenoble.fr0476767409
Bordeaux, 33076, France
loicsentilhes@hotmail.com05 56 79 56 79
Caen, 14003, France
Colombes, 92700, France
Grenoble, 38000, France
Lille, 59037, France
Marseille, 13915, France
Paris, 75014, France
Paris, 75014, France
Paris, 75019, France
Paris, 94270, France
Poissy, 78300, France
Rouen, 76031, France
Saint-Etienne, 42055, France
Strasbourg, 67200, France
Toulouse, 31059, France
benoist-gu@chu-caen.fr02 31 27 25 32
laurent.mandelbrot@aphp.fr01 47 60 63 39
PHoffmann@chu-grenoble.fr04 76 76 92 23
Veronique.DEBARGE@CHRU-LILLE.FR03 20 44 67 99
Florence.BRETELLE@ap-hm.fr04 91 96 46 72
gilles.grange@aphp.fr01 58 41 39 39
gilles.kayem@inserm.fr01 44 73 51 18
thomas.schmitz@rdb.aphp.fr01 40 03 20 00
marie-victoire.senat@aphp.fr01 45 21 77 64
prozenberg@chi-poissy-st-germain.fr01 39 27 52 57
Eric.Verspyck@chu-rouen.fr02.32.88.56.43
tiphaine.barjat@chu-st-etienne.fr04 77 82 83 83
Bruno.Langer@chru-strasbourg.fr03 88 12 75 02
christophe.vayssiere@gmail.com05 67 77 13 79
franck.perrotin@me.com02 47 47 47 39